No Data
November 13th A-share Investment Lightning Rod: Bona Film Group - several shareholders plan to reduce their shareholding by no more than 3.9754%; Ningbo Runhe High-Tech Materials - shareholders plan to jointly reduce their shareholding by no more than 2.0
Bona Film Group's multiple shareholders plan to reduce their shareholding by no more than 3.9754%; Ningbo Runhe High-Tech Materials' shareholders plan to collectively reduce their shareholding by no more than 2.00%; Lanwei Medical's shareholder, Ocean Wide Holdings Group, plans to reduce their shareholding by no more than 2%; Shanghai Sunglow Packaging Technology indicates additional investment in jintaike involves new business areas with uncertain expected returns; Zhengping Road & Bridge Construction received a warning letter from the Qinghai Regulatory Bureau of the CSRC; AsiaInfo Security received a warning letter from the Jiangsu Regulatory Bureau.
Lanwei Medical (301060.SZ): has repurchased 0.50% of the shares.
Grain Stockpile November 1st丨Lanwei Medical (301060.SZ) announced, as of October 31, 2024, the company repurchased a total of 1,996,100 shares of the company through the Shenzhen Stock Exchange stock trading system through centralized competitive bidding trading, accounting for 0.50% of the current total share capital of the company. The highest fill price was 14.23 yuan/share, the lowest fill price was 8.12 yuan/share, and the total fill amount was RMB 23.0046 million yuan (excluding transaction fees).
Lanwei Medical: Report for the third quarter of 2024
Shanghai Labway Clinical Laboratory Co., Ltd's (SZSE:301060) 50% Share Price Surge Not Quite Adding Up
Estimating The Fair Value Of Shanghai Labway Clinical Laboratory Co., Ltd (SZSE:301060)
Lanwei Medical (301060.SZ): The shares issued before the initial public offering of 0.217 billion shares will be unlocked on September 13.
Gelonghui September 9th | Lanwei Medicine (301060.SZ) announced a preliminary announcement of the first public issuance of shares that had been issued and listed for circulation. The number of shares to be released from restrictions and listed for circulation this time is 0.217 billion shares, accounting for 54.10% of the total share capital of the company, with a lock-up period of 36 months from the date of the company's first public offering and listing. The date of release of the restricted shares for listing and circulation is September 13, 2024 (Friday).
Investors Give Shanghai Labway Clinical Laboratory Co., Ltd (SZSE:301060) Shares A 27% HidingNo Data
No Data
